May 19 (Reuters) - Pfizer PFE.N has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc 1530.HK for the development, manufacturing and commercialization of a drug undergoing trials for treatment of certain types of cancer and tumours, the U.S. drugmaker said on Monday.
(Reporting by Kanjyik Ghosh; Editing by Alan Barona)
((Kanjyik.Ghosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.